Table 1.

Patient characteristics

HCsHOVON139 baseline PBHOVON139 baseline LNHOVON139 1-y PBHOVON141 baseline PBHOVON141 1-y PB
N104128111010
Males, %5075.780.881.830.030.0
Age, y63 (45-78)71 (57-80)71 (57-79)71.5 (60-78)68 (52-76)68 (52-76)
CMV positive, %83414864Not knownNot known
ALC, ×109/LNot known98.6 (3.5-420.7)97.3 (18.0-399.0)4.8 (2.8-9.9)129.8 (20.0-248.9)4.8 (3.9-7.6)
TTFT, moN/A28.2 (0.7-244.6)28.1 (0.7-244.6)18.9 (1.7-244.6)Not knownNot known
Prior treatment, nN/AN/AN/AN/A1 (1-3)1 (1-3)
Prior chemotherapy, %N/AN/AN/AN/A100100
TTT, moN/AN/AN/AN/A42.8 (13.8-141.8)42.8 (13.8-141.8)
Rai stage III-IV, %N/A57.144.036.48080
IgVH status U-CLL, %N/A55.955.627.34040
  • Unless otherwise noted, data are median (range).

  • ALC, absolute leukocyte count; CMV, cytomegalovirus; N/A, not applicable; TTFT, time to first treatment; TTT, time from last treatment to current treatment; U-CLL, CLL with unmutated immunoglobulin heavy chains.